Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0014848 (achalasia)
 2,804 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The purpose of this paper is to report the experience acquired in pneumatic dilatation in achalasia of the esophagus up to 1990. Two hundred and six patients were studied in that period (X 50, 7 years, M/F 1:1). According to X Rays the distribution was: grade I 17.4%, grade II 54.8%, grade III 14% and grade IV 13.5%. The associated esophageal pathology was: hiatus hernia 9.7%, esophagitis 5.8%, benign stenosis 2.4%, cancer 1.4%, ulcer and diverticula 0.9% and Schatzki's ring and leiomyoma 0.4% respectively Serology for Chagas disease was positive in 23% Chagasic megacolon was more frequent than chagasic heart disease (4.3% Vs. 1.4%). Out of these, one hundred and twenty patients were treated by pneumatic dilatation. To this group we shall refer in more detail. One hundred ant two patients were dilated once and the remaining 18 twice. Esophageal manometry showed a vigorous pattern in 7.7%. The LES' pressure pre-treatment was 24.5 mm Hg and post-dilatation 13.7 mm Hg in 75.8% of the cases the result was good. The morbidity was 5% and the mortality 0.7%. Relapse was seen in 25.8% of the cases. The follow-up was X 38 months. We conclude that pneumatic dilatation is the election procedure in the treatment of achalasia since it offers good results with low morbimortality. Surgery is indicated after failure of 2 dilatations, in children, and association with esophageal neoplasms, hiatus hernia and esophageal diverticula.
 ...
PMID:[Esophageal achalasia: 20 years' experience with non surgical treatment]. 181 99

With age, a person has "accumulation" of diseases. In patients of older age groups occurs simultaneously for at least 3-4 diseases. Assigning patients with ischemic heart disease (IHD), the physician takes into account the presence of concomitant diseases, especially diseases of the gastrointestinal tract, since the defeat of the stomach, liver, intestine may influence not only on the clinical course of heart disease, but also to change the pharmacokinetics of cardiac drugs. All groups of drugs used in treating coronary artery disease, have different effects on the digestive organs. This can be a positive influence. For example, the use of beta-blockers and nitrates for prevention of bleeding from esophageal varices at cirrhosis of the liver, calcium antagonists in achalasia cardia. It is well known, and the negative effect of cardiac drugs: erosive and ulcerative lesions of the stomach with aspirin use, increasing manifestations of GERD in patients receiving calcium antagonists (dihydropyridines group). In this regard, we need for rational pharmacotherapy.
 ...
PMID:[Cardiovascular pathology associated with digestive system diseases]. 2191 42